Napazimone clinical trials
Also written KL1333.
How each study uses napazimone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the napazimone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Abliva AB (2) · Pharming Technologies B.V. (2) · Yungjin Pharm. Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test napazimone.
- Oct 2027Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseasePhase 2 · Pharming Technologies B.V.
Studies
Open first, then newest update. How each study uses napazimone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial DiseaseRecruitingPhase 2Pharming Technologies B.V.NCT07514338Written as Napazimone
- Efficacy of KL1333 in Adult Patients With Primary Mitochondrial DiseaseRecruitingPhase 2Pharming Technologies B.V.NCT05650229Written as KL1333
- A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial DiseaseCompletedPhase 1Abliva ABNCT03888716Written as KL1333
- Drug-drug Interaction Study of KL1333 in Healthy SubjectsCompletedPhase 1Abliva ABNCT04643249Written as KL1333
- Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male VolunteersCompletedPhase 1Yungjin Pharm. Co., Ltd.NCT03056209Written as KL1333 25 mg
Codes
What other systems call napazimone · ClinicalTrials.gg INT017373
- UNII (FDA) NA2ZOL5UGMNAPAZIMONEOne source FDA
- NCI Thesaurus C213410NapazimoneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NA2ZOL5UGM | NAPAZIMONE | One source FDA |
| NCI Thesaurus | C213410 | Napazimone | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.